ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 1929

Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience
Abstract Number: 1930

Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Abstract Number: 1931

Anti-Ku Antibodies: A Case Series
Abstract Number: 1932

The Association Between Initial Ferritin and Complications from Adults Onset Stills Disease and Intensive Care Unit Admission
Abstract Number: 1933

Analysis of IgG4-Related Disease in a Diverse Long Island Population: Insights from the Rheumatology Clinic
Abstract Number: 1934

Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis
Abstract Number: 1935

Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Abstract Number: 1936

Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry
Abstract Number: 1937

Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis
Abstract Number: 1938

Cranial Nerve Manifestations in Sarcoidosis Associated with Lymphoma, Non-facial Paralysis, and Other Neurologic Disorders
Abstract Number: 1939

Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity
Abstract Number: 1940

A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features
Abstract Number: 1941

Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations
Abstract Number: 1942

Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases
Abstract Number: 1943

IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].